Latest News
2017.05.15

CTC and Mercodia enters a collaboration agreement

CTC Clinical Trial Consultants AB, based in Uppsala, and Mercodia also based in Uppsala are please to annonce that they have entered into a collaboration agreement.

 

Together the companies can offer their services in a combined package with both clinical services and high quality ELISAs in the areas of diabetes, obesity and cardiovascular disease.

 

CTC’s CEO, Anders Millerhovf, adds:

“Having a close collaboration with a high quality ELISA analysis lab can add substantial value to our clients. Early signals of clinical effect in early phase trials are crucial for many of our customers”

 

Mercodia , CEO, Mona Österberg, adds:

“We are very happy about this collaboration with the highly professional team at CTC, which is also a fellow Uppsala company. We believe that the combination of both companies’ core competences will increase the accuracy in the monitoring of clinical effects.

 

For more information CTC, please contact:
Anders Millerhovf – Chief Executive Officer
Telephone: +46 768 339 888

Email: anders.millerhovf@ctc-ab.se

www.ctc-ab.se

 

For more information Mercodia, please contact:

Name: Mona Österberg – Chief Executive Officer

Telephone: +46 18 570070

Email: info-europe@mercodia.com

Web: www.mercodia.com

 

About CTC Clinical Trial Consultants AB

CTC is a Swedish full-service CRO with clinical conduct in focus. Our mission is to facilitate clinical and translational research by providing our customers cost-effective advice and implementation of early clinical trials (Phase 0 / I / IIa). CTC has two dedicated research clinics in Uppsala (12 hospital beds, 12 non-hospital beds) in combination with two patient clinics located both in Uppsala and Linköping. Read more at ctc-ab.se

About Mercodia AB

Mercodia is dedicated to advancing innovative therapies for the prevention and treatment of metabolic diseases by providing immunoassay technology for clinical and research applications. We service a global market of over 100 countries with immunoassays spanning nine different species, covering both the basic and clinical research sectors, as well as in vitro diagnostics. Mercodia also offers GLP-compliant outsourcing services for small, preclinical studies to larger PI-PII clinical studies. Our bioanalytical, development, and production services are guided by FDA/EMA and CLSI guidelines, our extensive quality system and ISO 13485 for manufacturing medical devices. We specialize in large molecule ligand-binding assays, PK/PD/TK analysis, and offer a unique expertise in life cycle management. Read more at www.mercodia.com


Back to all News